Skip to content
    Compare notes on r/BodyHackGuideCompare notes with other researchers. Join r/BodyHackGuide

    Tesamorelin

    Growth Hormone / IGF-1 Axis

    Status
    FDA Approved
    Evidence

    Approved, human phase 3, graded on the CJC-1295 + Ipamorelin GH Secretagogue Bench

    Tesamorelin is a stabilized synthetic analog of human growth hormone-releasing hormone (GHRH): the full 44-amino-acid GHRH sequence with a single trans-3-hexenoyl fatty-acid modification at the N-terminus.

    Reviewed

    01Overview

    What Tesamorelin is

    The modification protects the peptide from rapid dipeptidyl peptidase-4 (DPP-4) degradation and extends its circulating half-life to approximately 30 minutes, against <2 minutes for native GHRH.

    Read the full overviewShow less

    Theratechnologies developed it and markets it in the US as Egrifta (branded injectable) and Egrifta SV (an updated formulation launched in 2019). It is the only FDA-approved GHRH secretagogue in the United States, approved in 2010 for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Approval rested on two Phase 3 trials showing an ~18% reduction in visceral adipose tissue (VAT) at 26 weeks, with the effect sustained through 52 weeks ([Falutz et al., 2007]; [Falutz et al., 2010]).

    Unlike CJC-1295 with DAC, tesamorelin raises GH in pulses rather than continuously. Its half-life is short enough to clear between pulses, so the negative-feedback regulation of the somatotroph axis stays intact. That is the main clinical reason it could be developed as a long-term therapy, where the continuous GH elevation of CJC-1295-DAC raised safety concerns.

    Beyond the FDA-approved HIV lipodystrophy indication, tesamorelin is being studied and used off-label:

    • In non-alcoholic fatty liver disease (NAFLD / NASH), a Phase 2 trial showed reductions in hepatic fat fraction and liver enzymes ([Stanley et al., 2014]).
    • For HIV-associated cognitive decline there are pilot data on executive function and memory ([Adrian et al., 2018]).
    • Biohackers use it off-label for general visceral adiposity in non-HIV, metabolically unhealthy adults.
    • It is added to CJC-1295 / MOD-GRF 1-29 plus ipamorelin stacks when GHRH-only amplification is wanted without the pulsatility trade-off of CJC-1295 with DAC.

    Typical dosing is 2 mg subcutaneous once daily, pre-bed, which matches the FDA-approved protocol. Doses above 2 mg/day have been studied, but they do not raise IGF-1 proportionally and they add to the fluid-retention burden.

    In the US it is FDA-approved for HIV lipodystrophy and available by prescription. Biohacker use is off-label, typically sourced through compounding pharmacies or (controversially) research-chemical vendors. The Tesamorelin Dosage Guide has the protocol specifics.

    How it works

    Tesamorelin activates the same GHRH receptor (GHRHR) as endogenous GHRH and CJC-1295 / MOD-GRF 1-29. Its trans-3-hexenoyl N-terminal modification gives it a distinct pharmacokinetic profile.

    Read the full mechanismShow less

    1. GHRH receptor agonism (Gs / cAMP / PKA / CREB pathway)

    • The peptide binds GHRHR, a Class B1 GPCR on anterior pituitary somatotrophs.
    • The activated receptor engages Gs and raises intracellular cAMP.
    • cAMP activates PKA, which phosphorylates CREB.
    • Phospho-CREB upregulates GH-1 gene transcription and mobilizes preformed GH from secretory granules.
    • The result is a GH pulse within 15-30 min of injection that peaks around 60 min.

    At GHRHR it is a full agonist, with binding affinity comparable to native GHRH and significantly higher potency than native GHRH because it stays in plasma longer ([Ferdinandi et al., 2007]).

    2. Preserved pulsatile GH release (key differentiator from CJC-1295-DAC)

    Tesamorelin's plasma half-life of ~30-50 minutes is short enough to clear between physiologic GH pulses and long enough to amplify endogenous pulses in a dose-dependent way. That timing preserves:

    • Somatotroph sensitivity, because continuous GHRH exposure (as with the ~8-day half-life of CJC-1295 with DAC) desensitizes pituitary receptors and tesamorelin's pulsatile exposure does not.
    • Somatostatin-mediated negative feedback, since between tesamorelin pulses somatostatin can appropriately suppress GH and so prevent supra-physiologic elevation.
    • Circadian integration, as the daily pre-bed dose amplifies the nocturnal GH burst rather than replacing it.

    This pulsatile exposure is the mechanistic reason tesamorelin could be developed as an approved drug where continuous-release GHRH analogs such as CJC-1295-DAC could not.

    3. Downstream IGF-1 elevation

    Acute GH pulses drive hepatic IGF-1 synthesis, which peaks ~24h post-dose. In the key Phase 3 trial, tesamorelin 2 mg daily raised mean IGF-1 by approximately 81% from baseline at week 26 (Falutz et al., 2007). At that point the FDA label reports 47% of patients above 2 SDS and 36% above 3 SDS.

    IGF-1 drives the downstream metabolic effects:

    • Lipolysis, preferentially in visceral adipose tissue, reduces VAT.
    • Hepatic triglyceride mobilization decreases hepatic steatosis.
    • Muscle protein synthesis preserves lean body mass.
    • Connective tissue anabolism speeds repair.

    4. Preferential visceral fat mobilization

    The most clinically distinctive effect is the preferential reduction of visceral adipose tissue over subcutaneous fat. In the pivotal trial, VAT fell ~15% at 26 weeks while subcutaneous abdominal fat changed little ([Falutz et al., 2007]). The selectivity comes from:

    • Higher -adrenergic receptor density on visceral adipocytes than on subcutaneous ones
    • Greater sensitivity of visceral fat to GH-mediated lipolysis
    • Portal delivery to the liver of visceral-origin FFAs, which the GH pulse mobilizes for oxidation

    5. Secondary effects beyond the GH axis

    • Hepatic fat falls independently of weight loss, through GH-driven hepatic lipid export ([Stanley et al., 2014]).
    • On cognition, a phase 2 randomized trial in people with HIV and abdominal obesity raised IGF-1 and reduced waist circumference but found no significant between-group improvement in neurocognitive performance versus standard of care ([Ellis et al., 2025]).
    • The pivotal and extension trials observed secondary lipid changes: a potential modest rise in HDL and fall in triglycerides.

    Studied for

    • HIV-associated lipodystrophy
    • Visceral adiposity
    • Cognitive aging
    • Metabolic syndrome

    Benefits listed

    • Reduction of visceral adipose tissue (~15% at 26 weeks in the pivotal HIV trial; FDA-label indication)
    • Reduction of hepatic fat content (NAFLD off-label indication)
    • Higher IGF-1 (mean rise of about 81% at 26 weeks in the main Phase 3 trial, PMID 18057338)
    • Preserved pulsatile GH release (vs continuous elevation with CJC-1295-DAC)
    Show 3 moreShow less
    • Improved body composition (VAT down, lean mass preserved)
    • Sustained VAT reduction through 52 weeks with continued dosing
    • FDA-approved, the only GHRH secretagogue with that status

    02Research

    Free with email

    What the research shows

    Graded on a research bench

    Reference pages that put Tesamorelin next to the compounds people pair it with: roles, evidence, overlap and conflicts. No dosing. Research use only.

    Unlock the research summary

    Enter your email to keep reading. It is free, and it opens these sections on every compound page in this browser.

    • A summary of the key research
    • Safety and side effects
    • A link to the PubMed results

    You also get the free peptide cheat sheet by email. Unsubscribe anytime.

    Have an account? Sign in

    03Safety

    Tesamorelin side effects and interactions

    Side effects

    Low risk

    Stop use if

    • Active malignancy
    • Pregnancy
    • Pituitary surgery or radiation history
    • Acute illness

    Common

    • Injection site reactions
    • Fluid retention
    • Arthralgias
    • Myalgias

    Less common

    • Elevated IGF-1
    • Glucose intolerance
    • Peripheral edema

    Who should not use it

    Contraindications

    Absolute contraindications (per FDA label)

    • Disruption of the hypothalamic-pituitary axis (pituitary tumor or removal, hypopituitarism, hypothalamic injury) rules it out. Tesamorelin requires an intact pituitary to work and can potentially accelerate residual tumor growth.
    • In active malignancy the GH/IGF-1 axis may accelerate tumor growth. It is an absolute contraindication during active cancer treatment or within 5 years of complete remission.
    • Do not use it in pregnancy (category X).
    • GH elevation can worsen active proliferative or severe non-proliferative diabetic retinopathy.
    • Known hypersensitivity to tesamorelin or mannitol (an excipient in the commercial formulation) also excludes it.
    Read all the contraindications and cautionsShow less

    Additional off-label biohacking contraindications

    • Uncontrolled T2DM should be optimized before starting, because tesamorelin acutely impairs glucose tolerance.
    • Active diabetic retinopathy counts at any grade, even non-proliferative.
    • A history of acromegaly or pituitary adenoma is an absolute contraindication.
    • In severe heart failure (NYHA III-IV), fluid retention can precipitate decompensation.
    • Tesamorelin is not safe during severe acute illness (sepsis, post-surgical critical care), which mirrors the recombinant GH warnings on acute critical illness.

    Relative contraindications (consult physician before use)

    • Type 2 diabetes or pre-diabetes calls for monitoring; expect HbA1c to rise ~0.1-0.3 points.
    • In uncontrolled hypertension, fluid retention can exacerbate blood pressure.
    • With a history of carpal tunnel syndrome, fluid retention can reactivate symptoms.
    • In hypothyroidism, optimize thyroid status first, since thyroid status affects the GH axis.
    • Above age 70, efficacy data are limited, and safety data from HIV trials do not include most elderly populations.

    Drug interactions

    • Chronic systemic glucocorticoids suppress the GH axis and blunt tesamorelin's efficacy.
    • Insulin and oral hypoglycemics may require dose adjustments because of tesamorelin's effect on glucose tolerance.
    • Tesamorelin is not a CYP3A4 inhibitor or inducer, so interactions with CYP3A4 substrates are minimal.
    • Do not combine it with exogenous recombinant GH, which is redundant.
    • Do not use other GHRH analogs simultaneously at the same receptor.

    Monitoring requirements

    • At baseline, check fasting glucose, IGF-1, HbA1c, a complete metabolic panel, thyroid (TSH, free T4), PSA (men >40), CBC and a lipid panel.
    • At week 4-6, check IGF-1; the target is within the age-adjusted reference range, typically <250 ng/mL for adults 30-50.
    • Every 12 weeks on therapy, check IGF-1, HbA1c and fasting glucose.
    • Annually, run the full panel and reassess the need for continued therapy.

    Discontinuation criteria

    Stop tesamorelin and consult a clinician on any of these:

    • IGF-1 > age-adjusted upper limit
    • HbA1c rising >0.4 points within one cycle
    • Persistent peripheral edema or new carpal tunnel symptoms
    • Any new palpable mass, a changing mole or unexplained weight loss (cancer workup indicated)
    • Severe headache, visual changes (rule out pituitary pathology)
    • Signs of fluid overload or CHF decompensation

    Interactions

    4 pairings in our record: 2 to avoid, 1 with a caution and 1 noted as compatible or synergistic. Compatible and synergistic are notes from the record, not safety findings.

    • Sermorelin

      Avoid

      Redundant GHRH analogs

    • CJC-1295

      Avoid

      Redundant GHRH analogs

    • MK-677

      Caution

      Risk of excessive sustained GH elevation

    • Ipamorelin

      Synergistic

      GHRH + GHRP synergy for optimized GH release

    This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.

    Need bloodwork before starting?

    Full hormone + metabolic panels from Anabolic Insights. Code CHONCH for first-order discount.

    Order Bloodwork

    04Dosing

    Free with email

    Tesamorelin dosage and protocols

    Dose range
    1,000–2,000 mcg (1–2 mg) daily
    Dosing
    Once daily subcutaneous injection
    Common vials
    2mg, 10mg

    Unlock the dosing protocols

    Enter your email to keep reading. It is free, and it opens these sections on every compound page in this browser.

    • Dose, route, how often and how long
    • A titration schedule
    • Beginner, intermediate and advanced protocols
    • Reconstitution and handling notes

    You also get the free peptide cheat sheet by email. Unsubscribe anytime.

    Have an account? Sign in

    05Prices

    Tesamorelin prices

    5 listings from 3 vendors, opening in the Featured order.

    Pack prices
    $44.99 to $84.99
    Lowest per mg
    $6.00/mg
    Vendors
    3
    Listings
    5 (vial)

    Prices as the vendors list them, last recorded 8 October 2026.

    Size
    Form
    Sort
    Tesamorelin listings, in Featured order
    VendorProductPriceBuy

    BH-Morelin 10mg

    vial, 1 vial

    In stock

    $8.50/mg

    $84.99

    Buy BH-Morelin 10mg at BHG Labs

    Tesamorelin 10mg

    vial, 1 vial

    In stock

    $6.00/mg

    $59.99

    Lowest per mg
    Buy Tesamorelin 10mg at BioMyst Labs

    Tesamorelin 10mg

    vial, 1 vial

    In stock

    $7.00/mg

    $69.99

    Buy Tesamorelin 10mg at BioMyst Labs

    Tesamorelin 2mg

    vial, 2mg vial

    In stock

    $22.50/mg

    $44.99

    Buy Tesamorelin 2mg at Half Nattys

    Tesamorelin 5mg

    vial, 5mg vial

    In stock

    $14.00/mg

    $69.99

    Buy Tesamorelin 5mg at Half Nattys
    Vendors selling Tesamorelin(3: trust score, certificates, payment, shipping)

    Every supplier above is graded 0 to 100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank. How we score these vendors

    Price history(3 days with a recorded price)
    Review Tesamorelin

    Sign in to leave a review

    Reviews on BodyHackGuide are tied to verified user accounts and moderated before publishing. Sign in (free, no spam) to share your experience with Tesamorelin.

    06Chemistry

    Chemistry and structure

    Molecular formula
    C221H366N72O67S
    Molecular mass
    5135.8 g/mol
    CAS number
    218949-48-5
    IUPAC name
    trans-3-hexenoyl-GHRH(1-44)amide
    Amino acid sequence
    trans-3-hexenoyl-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2 (single-letter: YADAIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGARARL). Tesamorelin is human GHRH(1-44) bearing an N-terminal trans-3-hexenoyl group on Tyr1 and a C-terminal amide. Molecular formula C221H366N72O67S; molecular weight ~5135.9 Da.
    Half-life
    8 to 11 minutes in healthy subjects (EGRIFTA SV and EGRIFTA WR labels)
    View on PubChem

    08Questions

    Frequently asked questions

    What is tesamorelin and what is it FDA-approved for?

    Tesamorelin is a stabilized synthetic analog of human growth hormone-releasing hormone (GHRH): the full 44-amino-acid sequence with a trans-3-hexenoyl N-terminal modification that extends its plasma half-life to ~30-50 minutes. It is FDA-approved (2010) for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, and Theratechnologies markets it as Egrifta / Egrifta SV. No other GHRH secretagogue is FDA-approved in the United States. Approval was based on two Phase 3 trials showing a ~15-18% reduction in visceral adipose tissue (VAT) at 26 weeks (Falutz et al., 2007).

    How is tesamorelin different from CJC-1295 with DAC?

    Both activate the GHRH receptor (GHRHR), but their pharmacokinetics are fundamentally different. Tesamorelin's 30-50 minute half-life is short enough to clear between physiologic GH pulses, so the pulsatile architecture and somatostatin-mediated negative feedback are preserved. CJC-1295 with DAC binds albumin, which stretches its half-life to ~8 days and produces continuous, non-pulsatile GH elevation. The continuous elevation of CJC-1295-DAC drives long-term safety concerns (somatotroph desensitization, supra-physiologic IGF-1, theoretical acromegalic progression) that tesamorelin avoids. That is the main mechanistic reason tesamorelin could become an FDA-approved drug and CJC-1295 with DAC could not.

    What's the correct dose and how often should I inject tesamorelin?

    The FDA-approved dose is 2 mg subcutaneous, once daily, pre-bed and fasted. All the Phase 3 trials used it, and it is the standard for both the HIV lipodystrophy label indication and off-label biohacker use. Doses above 2 mg/day have been studied (up to 4 mg) and do not produce a proportional IGF-1 rise: the dose-response plateaus while the side-effect burden climbs. Fasting is essential, because post-meal dosing blunts the GH pulse by 50-70%. Pre-bed timing uses the body's largest natural GH pulse, the nocturnal burst.

    Is tesamorelin safer than injecting actual growth hormone (somatropin)?

    Mechanistically, yes. Tesamorelin amplifies the body's own pulsatile GH release through the pituitary, so negative feedback and the physiologic pulse architecture stay intact. Exogenous somatropin bypasses the pituitary, produces tonic, non-pulsatile GH elevation and carries an FDA black-box warning for critical-illness mortality, while tesamorelin has no black-box warning. Both still sit inside the same GH/IGF-1 safety envelope: active malignancy, diabetic retinopathy and pituitary tumors are absolute contraindications for each. Tesamorelin is FDA-approved for one specific indication (HIV lipodystrophy) and somatropin for several. Neither is a direct replacement for the other.

    How much visceral fat can I expect to lose on tesamorelin?

    In the FDA Phase 3 trials, patients on tesamorelin 2 mg/day lost about 15% of their visceral adipose tissue (VAT) at 26 weeks and kept the reduction through 52 weeks of continued dosing (Falutz et al., 2007; Falutz et al., 2010). The loss favors visceral over subcutaneous fat; subcutaneous abdominal fat changed little in the same trials. Waist circumference typically shrinks a visible 1-3 cm. The effect plateaus around 26-52 weeks, and patients who discontinue regain VAT within 26 weeks, because the drug suppresses visceral fat without curing it. Biohacker results in non-HIV populations are less systematically documented but generally consistent with the HIV lipodystrophy data when combined with proper diet and training.

    What are the common side effects of tesamorelin?

    This is the profile the Phase 3 trials documented for the FDA. Common effects are injection site reactions (25% against 14% on placebo in the first 26 weeks), arthralgia (joint aches), mild peripheral edema, myalgia and pain in the extremities. Carpal tunnel symptoms (fluid-shift-mediated), hand paresthesias and glucose intolerance are uncommon. Less common are hypersensitivity reactions and new-onset diabetes (an HbA1c of 6.5% or more in 5% of treated patients by week 26, against 1% on placebo). Most effects are dose-dependent and resolve with dose reduction or cessation. Tesamorelin has no FDA boxed warning. On long-term therapy, monitor fasting glucose, IGF-1 and HbA1c quarterly.

    Can I stack tesamorelin with ipamorelin or semaglutide?

    Yes. Tesamorelin plus ipamorelin is the canonical biohacking GHS stack: 2 mg tesamorelin and 200 mcg ipamorelin in the same pre-bed injection produce a GH pulse 3-5x larger than either agent alone, through GHRH x ghrelin receptor synergy. Tesamorelin with semaglutide or tirzepatide is an effective body recomposition stack, in which GLP-1 drives the caloric deficit while tesamorelin plus ipamorelin preserves lean mass and preferentially reduces visceral fat. Do not stack tesamorelin with CJC-1295 with DAC (contradictory pharmacodynamics) or with recombinant GH (redundant and mechanistically confused).

    Does tesamorelin work for NAFLD (fatty liver disease)?

    Yes, off-label, and two randomized trials support it. In a 6-month trial of 50 HIV-infected adults with abdominal fat accumulation, tesamorelin 2 mg/day reduced liver fat with a net treatment effect of about -2.9% (lipid-to-water percentage), alongside a significant reduction in visceral fat (Stanley et al., 2014, JAMA). A larger 12-month trial in 61 HIV patients with confirmed NAFLD (hepatic fat fraction ≥5%) found that tesamorelin cut hepatic fat fraction by an absolute 4.1%, a 37% relative reduction from baseline, and 35% of treated patients reached a hepatic fat fraction below 5% against 4% on placebo (Stanley et al., 2019, Lancet HIV). The mechanism is GH-driven hepatic lipid export plus reduced portal free-fatty-acid flux from visceral fat. For documented NAFLD, the off-label framework is a 6-12 month tesamorelin protocol with periodic liver-enzyme monitoring and MRI-PDFF at baseline and follow-up. The FDA has not approved tesamorelin for NAFLD, so use is physician-supervised and off-label.

    Is tesamorelin legal and how do I get it?

    In the US, tesamorelin is FDA-approved and available by prescription, marketed as Egrifta SV by Theratechnologies. The FDA-approved indication is HIV-associated lipodystrophy. Off-label prescribing for non-HIV visceral adiposity or NAFLD depends on the physician and is less common because of insurance coverage limitations. Compounding pharmacy versions are available through integrative medicine clinics and typically cost less than branded Egrifta. Research-chemical grade tesamorelin is sold online, but quality varies enormously, and users should verify it with HPLC/mass spec COAs before use. The Best Peptide Vendors 2026 guide lists vetted sources. Legal status for personal use varies by jurisdiction.

    How long does tesamorelin take to work?

    The Phase 3 data give this timeline. (1) IGF-1 elevation is detectable at week 2 and reaches steady state by week 4-6. (2) Sleep quality and subjective recovery improve in weeks 1-3. (3) Waist circumference falls measurably at week 8-12, typically by 1-2 cm. (4) Visceral fat (VAT), measured by CT or DEXA, starts to fall measurably at week 12 and is down ~15% at week 26. (5) Hepatic fat (NAFLD) falls detectably at 3-6 months with continued therapy. (6) The effect plateaus around 26-52 weeks of continuous therapy. After discontinuation the effect reverses gradually over 6-12 months, because tesamorelin suppresses visceral adiposity rather than curing it.

    How many vendors sell Tesamorelin, and what does it cost per mg?

    3 of the vendors BodyHackGuide tracks list Tesamorelin (5 listings). Among BodyHackGuide's Tesamorelin listings recorded as in stock with a milligram count, the lowest price per milligram is $6.00/mg at BioMyst Labs and the median is $8.50/mg. The Tesamorelin prices on BodyHackGuide are vendors' listed prices as BodyHackGuide last recorded them, not transactions; the most recent recorded change to a Tesamorelin listing is dated 8 October 2026.

    Which vendors have third-party COAs for Tesamorelin on file at BodyHackGuide?

    BodyHackGuide holds 293 third-party certificate records for Tesamorelin, from Half Nattys and BHG Labs. An editor has read 1 of BodyHackGuide's 293 certificate records for Tesamorelin and recorded the laboratory, the compound and the test date as printed on each. The laboratories named on BodyHackGuide's Tesamorelin certificate records are Freedom Diagnostics Testing and ILS Laboratories, and the newest test date on them is 6 October 2026. Each vendor page on BodyHackGuide shows how many certificate records BodyHackGuide holds for that vendor and links to each record that has its own page.

    Related

    Articles on Tesamorelin

    Free 2026 Peptide Cheat Sheet (PDF)

    38 compounds and blends: vial sizes, BAC water volumes, dosing ranges and bloodwork markers.

    Download Free